Hybio is a hi-tech enterprise specialized in the research and development, as well as manufacturing, of diverse peptide products. The company has established itself as a leading pharmaceutical provider and became the first peptide-focused enterprise to go public in China in 2011 (stock code 300199). Hybio offers a comprehensive range of peptide products, including both Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDFs). While its peptide FDFs primarily cater to the Chinese domestic market, its APIs are supplied to clients worldwide. The company's headquarters in Shenzhen has successfully passed local and national NMPA GMP inspections multiple times.

Services include:
- APIs (Active Pharmaceutical Ingredients)
- FDFs (Finished Dosage Forms)
- CRO (Contract Research Organisation)
- CDMO (Contract Development and Manufacturing Organisation)

Hybio continues to advance the pharmaceutical industry with its diverse offerings and expertise. For more information, readers are encouraged to visit hybio.lookchem.com.